Literature DB >> 27316999

A High-Throughput Flow Cytometry Assay for Identification of Inhibitors of 3',5'-Cyclic Adenosine Monophosphate Efflux.

Dominique Perez1, Peter C Simons1, Yelena Smagley1, Larry A Sklar2, Alexandre Chigaev1.   

Abstract

Assays to identify small molecule inhibitors of cell transporters have long been used to develop potential therapies for reversing drug resistance in cancer cells. In flow cytometry, these approaches rely on the use of fluorescent substrates of transporters. Compounds which prevent the loss of cell fluorescence have typically been pursued as inhibitors of specific transporters, but further drug development has been largely unsuccessful. One possible reason for this low success rate could be a substantial overlap in substrate specificities and functions between transporters of different families. Additionally, the fluorescent substrates are often synthetic dyes that exhibit promiscuity among transporters as well. Here, we describe an assay in which a fluorescent analog of a natural metabolite, 3',5'-cyclic adenosine monophosphate (F-cAMP), is actively effluxed by malignant leukemia cells. The F-cAMP is loaded into the cell cytoplasm using a procedure based on the osmotic lysis of pinocytic vesicles. The flow cytometric analysis of the fluorescence retained in F-cAMP-loaded cells incubated with various compounds can subsequently identify inhibitors of cyclic AMP efflux (ICE).

Entities:  

Keywords:  ABC transporters; Cyclic AMP; Efflux inhibitors; Fluorescent substrates; High-throughput flow cytometry

Mesh:

Substances:

Year:  2016        PMID: 27316999      PMCID: PMC6269090          DOI: 10.1007/978-1-4939-3673-1_15

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  15 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

Review 2.  Dihydropyridines and multidrug resistance: previous attempts, present state, and future trends.

Authors:  Abdolhossein Zarrin; Ahmad R Mehdipour; Ramin Miri
Journal:  Chem Biol Drug Des       Date:  2010-11       Impact factor: 2.817

3.  Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation.

Authors:  Sabrina Copsel; Corina Garcia; Federico Diez; Monica Vermeulem; Alberto Baldi; Liliana G Bianciotti; Frans G M Russel; Carina Shayo; Carlos Davio
Journal:  J Biol Chem       Date:  2011-01-04       Impact factor: 5.157

4.  Introduction of macromolecules into cultured mammalian cells by osmotic lysis of pinocytic vesicles.

Authors:  C Y Okada; M Rechsteiner
Journal:  Cell       Date:  1982-05       Impact factor: 41.582

5.  Modulation of high affinity ATP-dependent cyclic nucleotide transporters by specific and non-specific cyclic nucleotide phosphodiesterase inhibitors.

Authors:  Lena Aronsen; Elin Orvoll; Roy Lysaa; Aina W Ravna; Georg Sager
Journal:  Eur J Pharmacol       Date:  2014-11-07       Impact factor: 4.432

Review 6.  What do drug transporters really do?

Authors:  Sanjay K Nigam
Journal:  Nat Rev Drug Discov       Date:  2014-12-05       Impact factor: 84.694

Review 7.  Mechanisms and strategies to overcome multiple drug resistance in cancer.

Authors:  Tomris Ozben
Journal:  FEBS Lett       Date:  2006-02-17       Impact factor: 4.124

8.  ABC transporters in cancer: more than just drug efflux pumps.

Authors:  Jamie I Fletcher; Michelle Haber; Michelle J Henderson; Murray D Norris
Journal:  Nat Rev Cancer       Date:  2010-01-15       Impact factor: 60.716

9.  The role of cyclic nucleotide signaling pathways in cancer: targets for prevention and treatment.

Authors:  Alexandra M Fajardo; Gary A Piazza; Heather N Tinsley
Journal:  Cancers (Basel)       Date:  2014-02-26       Impact factor: 6.639

Review 10.  ABC transporters in CSCs membranes as a novel target for treating tumor relapse.

Authors:  Laura Zinzi; Marialessandra Contino; Mariangela Cantore; Elena Capparelli; Marcello Leopoldo; Nicola A Colabufo
Journal:  Front Pharmacol       Date:  2014-07-10       Impact factor: 5.810

View more
  4 in total

Review 1.  Clioquinol: To harm or heal.

Authors:  Dominique R Perez; Larry A Sklar; Alexandre Chigaev
Journal:  Pharmacol Ther       Date:  2019-03-18       Impact factor: 12.310

2.  NQO1 protects against clioquinol toxicity.

Authors:  Jamuna Chhetri; Jem Dilek; Noel Davies; Glenn Jacobson; Robert Dallmann; Nuri Gueven
Journal:  Front Pharmacol       Date:  2022-10-04       Impact factor: 5.988

Review 3.  Drug repurposing for targeting cyclic nucleotide transporters in acute leukemias - A missed opportunity.

Authors:  Dominique R Perez; Larry A Sklar; Alexandre Chigaev; Ksenia Matlawska-Wasowska
Journal:  Semin Cancer Biol       Date:  2020-02-07       Impact factor: 15.707

4.  Founder genetic variants of ABCC4 and ABCC11 in the Japanese population are not associated with the development of subacute myelo-optico-neuropathy (SMON).

Authors:  Hideki Matsumoto; Hideo Sasai; Norio Kawamoto; Masato Katsuyama; Makoto Minamiyama; Satoshi Kuru; Toshiyuki Fukao; Hidenori Ohnishi
Journal:  Mol Genet Genomic Med       Date:  2021-12-24       Impact factor: 2.473

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.